200,000+ products from a single source!
sales@angenechem.com
Home > Indoles and Oxindole > 150375-75-0
150375-75-0 | 2-Pyrrolidinecarboxamide, 1-[[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-, (2S)-
CAS No: 150375-75-0 Catalog No: AG001MJV MDL No:
Product Description
Catalog Number:
AG001MJV
Chemical Name:
2-Pyrrolidinecarboxamide, 1-[[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-, (2S)-
CAS Number:
150375-75-0
Molecular Formula:
C28H27Cl2N3O7S
Molecular Weight:
620.5009
IUPAC Name:
(2S)-1-[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxyphenyl)sulfonyl-3-hydroxy-2H-indole-2-carbonyl]pyrrolidine-2-carboxamide
InChI:
InChI=1S/C28H27Cl2N3O7S/c1-39-23-12-10-17(15-24(23)40-2)41(37,38)33-21-11-9-16(29)14-19(21)28(36,18-6-3-4-7-20(18)30)25(33)27(35)32-13-5-8-22(32)26(31)34/h3-4,6-7,9-12,14-15,22,25,36H,5,8,13H2,1-2H3,(H2,31,34)/t22-,25-,28+/m0/s1
InChI Key:
CEBYCSRFKCEUSW-NAYZPBBASA-N
SMILES:
COc1ccc(cc1OC)S(=O)(=O)N1c2ccc(cc2[C@]([C@@H]1C(=O)N1CCC[C@H]1C(=O)N)(O)c1ccccc1Cl)Cl
UNII:
C1GL8G6G0O
Properties
Complexity:
1090
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
3
Defined Bond Stereocenter Count:
0
Exact Mass:
619.095g/mol
Formal Charge:
0
Heavy Atom Count:
41
Hydrogen Bond Acceptor Count:
8
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
620.498g/mol
Monoisotopic Mass:
619.095g/mol
Rotatable Bond Count:
7
Topological Polar Surface Area:
148A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.8
Literature
| Title | Journal |
|---|---|
| Vasopressin-2 receptor antagonist attenuates the ability of the lungs to clear edema in an experimental model. | American journal of respiratory cell and molecular biology 20121101 |
| Distinct receptor subtypes mediate arginine vasopressin-dependent ACTH release and intracellular calcium mobilization in rat pituitary cells. | European journal of pharmacology 20120315 |
| Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish. | Psychopharmacology 20120301 |
| The cardioprotective effect of different doses of vasopressin (AVP) against ischemia-reperfusion injuries in the anesthetized rat heart. | Peptides 20111201 |
| V2 receptor antagonist; tolvaptan. | Electrolyte & blood pressure : E & BP 20111201 |
| Oxytocin antagonists for the management of preterm birth: a review. | American journal of perinatology 20110601 |
| Role of vasopressin V(₁A) receptor in the urethral closure reflex in rats. | American journal of physiology. Renal physiology 20110401 |
| Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury. | Neurochemistry international 20110301 |
| The vasopressin Avpr1b receptor: molecular and pharmacological studies. | Stress (Amsterdam, Netherlands) 20110101 |
| Oxytocin and vasopressin V(1A) receptors as new therapeutic targets in assisted reproduction. | Reproductive biomedicine online 20110101 |
| Post-treatment with SR49059 improves outcomes following an intracerebral hemorrhagic stroke in mice. | Acta neurochirurgica. Supplement 20110101 |
| The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents. | International journal of endocrinology 20110101 |
| cAMP/PKA-dependent increases in Ca Sparks, oscillations and SR Ca stores in retinal arteriolar myocytes after exposure to vasopressin. | Investigative ophthalmology & visual science 20100301 |
| [Vasopressin receptor antagonists and heart failure]. | Therapeutische Umschau. Revue therapeutique 20091101 |
| Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure. | The Journal of pharmacology and experimental therapeutics 20080801 |
| Non-peptide arginine-vasopressin antagonists: the vaptans. | Lancet (London, England) 20080510 |
| Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema. | Acta neurochirurgica. Supplement 20080101 |
| The modulation of aquaporin-4 by using PKC-activator (phorbol myristate acetate) and V1a receptor antagonist (SR49059) following middle cerebral artery occlusion/reperfusion in the rat. | Acta neurochirurgica. Supplement 20080101 |
| Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. | Journal of medicinal chemistry 20071004 |
| Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. | American journal of physiology. Renal physiology 20070101 |
| Vasopressin antagonists. | Cellular and molecular life sciences : CMLS 20060801 |
| Pharmacological chaperone activity of SR49059 to functionally recover misfolded mutations of the vasopressin V1a receptor. | The Journal of biological chemistry 20060526 |
| Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells. | European journal of pharmacology 20060524 |
| Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. | The Journal of clinical endocrinology and metabolism 20060401 |
| Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents. | Autonomic & autacoid pharmacology 20060401 |
| Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. | Journal of the American Society of Nephrology : JASN 20060101 |
| Protective effect of the V1a receptor antagonist SR49059 on brain edema formation following middle cerebral artery occlusion in the rat. | Acta neurochirurgica. Supplement 20060101 |
| Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist. | British journal of pharmacology 20051101 |
| Vasotocin and vasopressin stimulation of the chloride secretion in the human bronchial epithelial cell line, 16HBE14o-. | British journal of pharmacology 20050401 |
| The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor. | Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20050201 |
| Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist. | Vascular pharmacology 20050101 |
| Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. | Molecular endocrinology (Baltimore, Md.) 20040801 |
| Participation of vasopressin in the development of cerebral vasospasm in a rat model of subarachnoid haemorrhage. | Clinical and experimental pharmacology & physiology 20040401 |
| Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. | Acta obstetricia et gynecologica Scandinavica 20040101 |
| Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors. | The Journal of biological chemistry 20031010 |
| Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas. | American journal of physiology. Endocrinology and metabolism 20030901 |
| Oxytocin and fetal membranes in preterm labor: current concepts and clinical implication. | Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20030601 |
| Vasopressin-induced facilitation of adrenergic responses in the rat mesenteric artery is V1-receptor dependent. | Autonomic & autacoid pharmacology 20030201 |
| Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. | Stroke 20021201 |
| Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor. | Journal of medicinal chemistry 20020606 |
| Interplay between presynaptic and postsynaptic activities is required for dendritic plasticity and synaptogenesis in the supraoptic nucleus. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20020101 |
| Placental transfer of SR49059 in the human dually perfused cotyledon in vitro. | Placenta 20011101 |
| Vascular and renal effects of vasopressin and its antagonists in conscious rats with chronic myocardial infarction; evidence for receptor shift. | European journal of pharmacology 20010706 |
| Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. | British journal of pharmacology 20010701 |
| A nonpeptide vasopressin V(1a) receptor antagonist, SR 49059, does not prevent cisplatin-induced emesis in piglets. | Fundamental & clinical pharmacology 20010601 |
| High concentrations of oxytocin cause vasoconstriction by activating vasopressin V1A receptors in the isolated perfused rat kidney. | Naunyn-Schmiedeberg's archives of pharmacology 20010401 |
| Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. | Naunyn-Schmiedeberg's archives of pharmacology 20000301 |
| Vasopressin does not effect hypertension caused by long-term nitric oxide inhibition. | Hypertension (Dallas, Tex. : 1979) 20000201 |
| Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. | British journal of obstetrics and gynaecology 19991001 |
| Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V1A receptors. | European journal of pharmacology 19990702 |
| Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. | British journal of pharmacology 19981201 |
| Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. | The Journal of biological chemistry 19971017 |
| The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. | Endocrinology 19971001 |
| Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes. | Biochemical and biophysical research communications 19940227 |
| Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. | The Journal of biological chemistry 19940204 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.